LADENBURG THALM/SH SH Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)

Analysts at LADENBURG THALM/SH SH started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report released on Wednesday. The firm set a “buy” rating and a $5.00 price target on the stock. LADENBURG THALM/SH SH’s target price would suggest a potential upside of 128.83% from the company’s previous close.

A number of other research analysts also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. Raymond James Financial cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 27th. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Finally, Stifel Nicolaus set a $6.00 price target on Compass Therapeutics in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.25.

Compass Therapeutics Stock Down 0.2%

Shares of NASDAQ CMPX traded down $0.01 during trading hours on Wednesday, hitting $2.19. The company had a trading volume of 185,090 shares, compared to its average volume of 5,127,127. The stock has a market capitalization of $393.50 million, a P/E ratio of -5.30 and a beta of 0.89. Compass Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.88. The firm’s 50 day moving average is $2.33 and its 200-day moving average is $4.48.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). On average, sell-side analysts predict that Compass Therapeutics will post -0.42 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Strs Ohio acquired a new position in shares of Compass Therapeutics in the first quarter valued at $34,000. Creative Planning acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $30,000. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $84,000. Invesco Ltd. boosted its holdings in shares of Compass Therapeutics by 58.1% during the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after buying an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after buying an additional 449,868 shares during the period. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.